• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

COVID-19 Raises Risk of MACE up to 3 Years Later: Daily Dose

News
Article
COVID-19 Raises Risk of MACE up to 3 Years Later: Daily Dose / Image Credit: ©New Africa/AdobeStock
©New Africa/AdobeStock

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.


On October 7, 2024, we reported on findings from a study published in Arteriosclerosis, Thrombosis, and Vascular Biology that examined the duration and underlying determinants of heightened risk of cardiovascular disease and major adverse cardiovascular events (MACE) post–COVID-19.

The study

Investigators identified 10 005 individuals from the UK Biobank with either a positive PCR test for SARS-CoV-2 or a hospital-based ICD-10 code for COVID-19 between February 1, 2020, and December 31, 2020. Vaccinated individuals were excluded from the analysis.

Risk for MACE (including myocardial infarction, stroke, or all-cause mortality) following infection and hospitalization in the cohort was compared to risk among population controls already in the UK Biobank who never received a positive PCR test for SARS-CoV-2 or were never assigned a COVID-19 ICD-10 code during the study period (n = 217 730) and another propensity-matched cohort (n = 38 860) to reduce confounding due to preexisting risk factors.

The findings

The risk of MACE was more than 2-times higher among those who had COVID-19 and nearly 4-times greater among those hospitalized with COVID-19 compared with individuals with no history of COVID-19 infection during the nearly 3-year follow-up, researchers reported.

Investigators also observed a significant genetic interaction between the ABO locus and hospitalization for COVID-19 (Pinteraction = .01), with the risk of thrombotic events higher among individuals with non-O blood types (HR 1.65, 95% CI 1.29-2.09; P = .000048 compared with those with blood type O (HR 0.96, 95% CI 0.66-1.39; P = .82; Pinteraction = .01).

Authors' comment

"Hospitalization for COVID-19 represents a coronary artery disease risk equivalent, with post–acute myocardial infarction and stroke risk particularly heightened in non-O blood types."

Click here for more details.


Related Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Related Content
© 2024 MJH Life Sciences

All rights reserved.